As we all know, Eli Lilly is close behind in the race with its oral GLP-1, orforglipron, which is expected to be approved by the FDA late in the first quarter
Lan T, Wang Y, Chen Y, Qin W, Zhang J, Wang Z, et al
Friedlander et al., 2012)
We first confirmed active GLP1RSPHKAP protein-protein interaction, inferred from our MS interactome analysis, by measuring increased co-immunoprecipitation of SPHKAP-EGFP (Fig
This can cause muscle weakness, stunted growth, an enlarged liver, and other dangerous conditions